Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, S. Fagiuoli, A. Albertí et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 19
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosisAntonio Ascione, N. Caporaso, M. De Luca et al.|Infection|2018Cited by 8